tradmap

GRCE Financials Grace Therapeutics, Inc.

8 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Revenue & net income
-$42M $29M $100M $0 2019 2020 2021 2022 2023 2024 2025 2026
RevenueNet income
Margins (gross / operating / net)
-16% 42% 100% 0% 2019 2020 2021 2022 2023 2024 2025 2026
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $1 $1 2019 2020 2021 2022 2023 2024 2025 2026
Free cash flow
Cash vs total debt
$0 $25M $51M 2019 2020 2021 2022 2023 2024 2025 2026
CashTotal debt
Cash flow: operating / investing / financing
-$23M $18M $59M $0 2019 2020 2021 2022 2023 2024 2025 2026
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2026 -$8M $17M
2025 -$10M $22M
2024 -$13M $23M
2023 -$42M $28M
2022 $100M -$10M 100.0% -15.6% $30M
2021 -$20M $51M
2020 -$26M $14M
2019 -$39M $17M

Frequently asked questions

Is GRCE growing its revenue and profit?

See the revenue and net-income charts above for Grace Therapeutics, Inc.'s multi-year trend.

How much debt does GRCE have?

As of FY2026, Grace Therapeutics, Inc. reported — of total debt against $17M of cash.

What is GRCE's profit margin?

In FY2026, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.